Japanese Bio Venture Company Transparent And Toyo Gosei Jointly Market Drug Discovery Screening Kit
This article was originally published in PharmAsia News
Executive SummaryChiba prefecture-based Transparent, a biology venture company funded by Tokyo University of Science and Toyo Gosei, a pharmaceutical material maker announced May 15 that they have jointly developed and marketed Cell-able, a drug discovery screening kit to culture liver cells in a close to in-vivo environment. Cell-able can be used to conduct 96 tests on a single plate which is eight times greater than current methods. Transparent hopes to reach ¥100 million in sales this year, and will launch Cell-able overseas next year and hopes to reach ¥3 billion in sales by 2012. (Click here for more - Japanese language
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.